Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

letter

. 2023 Sep 7;7(10):e954. doi: 10.1097/HS9.0000000000000954

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 1. — Comparison of 2-, 5-, and 10-year OS, NS, and PFS of the MCL2-treated trial-eligible and trial-ineligible groups and the other group, who did not receive MCL2 treatment. (A) OS at 2, 5, and 10 years. The trial-eligible group: 93% (95% CI, 89-98), 79% (95% CI, 71-87), and 57% (95% CI, 45-72). The trial-ineligible group: 84% (95% CI, 75-94), 59% (95% CI, 46-74), and 49% (95% CI, 34-70). The other group: 70% (95% CI, 65-75), 47% (95% CI, 41-53), and 17% (95% CI, 11-25). The OS was significantly improved in the trial-eligible and trial-ineligible groups compared with the other group (P < 0.001 in both comparisons). The median OS in the trial-eligible group was also improved compared with the trial-ineligible group (P < 0.001). (B) NS at 2, 5, and 10 years. The trial-eligible group: 95% (95% CI, 90-99), 82% (95% CI, 74-91), and 64% (95% CI, 51-80). The trial-ineligible group: 86% (95% CI, 77-96), 64% (95% CI, 51-81), and 61% (95% CI, 43-87). The other group: 76% (95% CI, 71-82), 60% (95% CI, 53-69), and 29% (95% CI, 20-44). NS was significantly improved in the trial-eligible and trial-ineligible groups compared with the other group (P < 0.001 in both comparisons). There was no statistically significant difference between the trial-eligible and trial-ineligible groups (P = 0.368). (C) PFS at 2, 5, and 10 years. The trial-eligible group: 81% (95% CI, 74-89), 62% (95% CI, 53-73), and 40% (95% CI, 29-56). The trial-ineligible group: 72% (95% CI, 62-85), 46% (95% CI, 34-62), and 23% (95% CI, 11-45). The other group: 57% (95% CI, 51-63), 30% (95% CI, 25-37), and 2% (95% CI, 0-13). PFS was significantly improved both in the trial-eligible group (P < 0.001) and trial-ineligible (P = 0.003) group compared with the other group. The median PFS in the trial-eligible group was also improved compared with the trial-ineligible group (P = 0.030). CI = confidence interval; MCL = mantle cell lymphoma; NS = net survival; OS = overall survival; PFS = progression-free survival.